[Form 4/A] Bionano Genomics, Inc. Amended Insider Trading Activity

Rhea-AI Filing Summary

Amended Form 4: Mark Oldakowski, Chief Operating Officer of Bionano Genomics, reported an amended insider transaction related to restricted stock units. On 09/11/2025 a grant of RSUs vested and the issuer withheld 59 shares to satisfy tax withholding obligations at a reported price of $4.06 per share. After the withholding, the reporting person beneficially owned 915 shares of Bionano Genomics common stock on a direct basis. The amendment was filed on 09/12/2025 and is limited to reporting the share withholding related to the RSU settlement that originally vested on 09/11/2025.

Positive

• Disclosure completed: The amendment clarifies the tax-withholding treatment of vested RSUs, improving transparency.
• Minimal dilution/ownership change: Only 59 shares were withheld, leaving the reporting person with 915 shares, which is a small ownership change.

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine tax-withholding on RSU settlement by a named executive; no change in control or new purchases reported.

The filing records a common corporate administrative action: the company withheld 59 shares from an RSU award to meet tax obligations when the RSUs vested on 09/11/2025. The reporting person is the COO and the amendment clarifies the withholding details. This does not alter beneficial ownership meaningfully (915 shares remaining) and contains no new compensatory grant, option exercise, or sale activity beyond the withholding.

Securities Analyst

TL;DR: Small-scale insider share withholding disclosed; immaterial to capitalization or control.

The transaction shows a withholding at a price of $4.06 per share for 59 shares related to vested RSUs from a 2023 award. The disclosure is administrative and does not reflect an open-market transaction or disposition that would signal a change in insider sentiment. The amended filing date of 09/12/2025 simply updates the Form 4 record.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

OLDAKOWSKI MARK

(Last) (First) (Middle)

C/O BIONANO GENOMICS, INC.

9540 TOWNE CENTRE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [ BNGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
09/12/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		F(1)		59(1)	D	$4.06	915	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is reporting the withholding by the Issuer an aggregate of 59 shares of common stock that vested on September 11, 2025, pursuant to an RSU award granted on September 11, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award.

Remarks:

	/s/ Jonathan V. Dixon, Attorney-in-Fact	09/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Mark Oldakowski report on the Form 4/A for BNGO?

The filing reports that 59 shares were withheld upon RSU vesting on 09/11/2025 to satisfy tax withholding; after the transaction he beneficially owned 915 shares.

Why were shares withheld in the reported transaction?

The document states the issuer withheld shares to satisfy the reporting person's tax withholding obligations upon settlement of an RSU award.

What price is shown for the withheld shares on the Form 4/A?

The price reported for the withheld shares is $4.06 per share.

When did the RSUs vest and when was the Form 4 amended?

The RSUs vested on 09/11/2025 and the amended Form 4 was filed on 09/12/2025.

Does this filing show any open-market purchases or sales by the reporting person?

No. The filing only reports share withholding to satisfy taxes upon RSU settlement; there are no open-market purchases or sales disclosed.